Abstract. Venous thromboembolism is a major cause of morbidity and mortality with a high recurrence rate. The present study aimed to explore the molecular mechanisms and potential biomarkers of single venous thromboembolism (SVTE) and recurrent venous thromboembolism (RVTE). The microarray dataset GSE19151 was downloaded from Gene Expression Omnibus, which contained data from whole blood samples from 63 healthy controls, 32 SVTE and 38 RVTE patients. Differentially expressed genes (DEGs) in the SVTE and RVTE groups compared with those in the controls were identified using the t-test, followed by clustering analysis of DEGs and samples. Functional and pathway enrichment analyses were performed for DEGs in patients with RVTE and SVTE, as well as specific DEGs in patients with RVTE. The identified 42 DEGs in RVTE were mainly enriched in biological processes of cellular protein metabolism, gene expression and translational elongation as well as in pathways associated with ribosomes, Parkinson's disease and oxidative phosphorylation. In SVTE, 20 DEGs were identified, which were mainly involved in biological processes of biopolymer biosynthesis, translational elongation and cellular protein metabolism as well as pathways associated with ribosomes and cardiac muscle contraction. In RVTE, 22 specific DEGs were mainly involved in translational elongation, negative regulation of the force of heart contraction by chemical signals, cell proliferation, ribosomal pathways and protein export. The identified DEGs of SVTE, including COX7C and UQCRQ, may be potential biomarkers for SVTE, and the specific DEGs of RVTE, including ADRBK1, NDUFA5 and ATP5O, may be potential biomarkers for RVTE.
Introduction
Venous thromboembolism (VTE), comprising deep venous thrombosis and pulmonary embolism, is a frequent disease with high morbidity and mortality, which affects 1-2 per 1,000 individuals (1) (2) (3) . Furthermore, VTE is associated with a significant rate of recurrence in as many as 30% of VTE patients after termination of the standard course of anti-coagulant therapy (4) (5) (6) . Therefore, it is desired to explore the molecular mechanisms and potential biomarkers that enable clinicians to identify patients at a risk of single VTE (SVTE) or recurrent VTE (RVTE) for prompt clinical diagnosis and early prevention (7) .
Kyrle et al (8) reported that patients with a high level of factor VIII have an increased risk of RVTE. A study by Comp and Esmon (9) suggested that the levels of protein S may be used in the evaluation of RVTE. Various established and novel biomarkers, including D-dimer, E-selectin, P-selectin, thrombin, inflammatory markers and C-reactive protein, have been investigated for their predictive value in SVTE and RVTE (10) (11) (12) (13) . However, only a small number of biomarkers, such as D-dimer, associated with a first or recurrent event of VTE were highlighted by these studies, while novel and promising biomarkers, including P-selectin and inflammatory cytokines, are still controversial (1) . A study by Lewis et al (14) performed a pathway enrichment analysis of differentially expressed genes (DEGs) in samples from patients with SVTE and samples from patients with RVTE and found that insulin-like growth factor receptor 1 and Akt pathways may be useful for distinguishing patients with SVTE from those with RVTE.
The present study identified DEGs in RVTE and SVTE, as well as specific DEGs in RVTE. Functional and pathway enrichment analyses for these DEGs were performed to explore the molecular mechanisms and potential biomarkers of SVTE and RVTE in order to facilitate the diagnosis and clinical therapy management of VTE.
Materials and methods
Affymetrix microarray data. The gene expression profile dataset GSE19151 was obtained from Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/), which was deposited by Lewis et al (14) . Microarray data from 133 whole -27 ) and cellular macromolecular biosynthetic processes (P=8.78x10 -6 ). In the cellular component category, enriched GO terms were mainly associated with the ribosomal sub-unit (P=2.03x10 -18 ), cytosol (P=2.43x10 -12 ) and macromolecular complexes (P=8.61x10 -11 ). In the molecular function category, GO terms enriched for DEGs in RVTE included structural constituents of ribosomes (P=9.13x10 -24 ), insulin-like growth factor binding (P=0.002) and beta-adrenergic receptor kinase activity (P=0.005) (Tables II-IV) .
In SVTE, the most significantly enriched GO terms for DEGs in biological processes included biopolymer biosynthesis (P=2.35x10 -5 ), translational elongation (P=2.35x10 -5 ), cellular protein metabolism (P=1.24x10 -7 ) and rRNA processing (P=0.006). The predominantly enriched GO terms of the cellular component category were the cytosol (P=1.68x10 -11 ), the cytosolic large ribosomal sub-unit (P=8.62x10 -10 ) and macromolecular complexes (P= 4.86x10 -9 ). The main GO terms of DEGs in SVTE in the molecular function category were structural constituents of ribosomes (P=4.69x10 -20 ), RNA binding (P=2.79x10 -5 ) and protein channel activity (P=0.001). Among the DEGs in SVTE, 12 genes, including RPS3A and RPS7, were involved in translational elongation, 2 genes (UQCRQ and COX7C) were involved in oxidoreductase activity and 2 genes (HINT1 and LAMP1) were associated with proteolysis (Tables II-IV) .
The GO terms for biological processes of the 22 specific DEGs of RVTE were mainly translational elongation (P=3.52x10 -7 ), negative regulation of the force of heart contraction by chemical signals (P=0.001) and cell proliferation (P=0.002). In the cellular component category, enriched GO terms were mainly associated with the cytosolic small ribosomal sub-unit (P=1.56x10 -5 ), ribosomal sub-unit (P=1.84x10 -5 ) and macromolecular complexes (P=0.0008). The specific GO terms of the 22 specific DEGs in RVTE in the molecular function category were mainly associated with structural constituents of ribosomes (P=2.55x10 -6 ), insulin-like growth factor binding (P= 0.0006), beta-adrenergic receptor kinase activity (P= 0.003) and phospholipase A2 inhibitor activity (P= 0.004). Two genes (IGF2R and IGFBP7) were shown to be involved in anti-apoptotic signaling, ten genes, including RPL21 and RPS21, were involved in translational elongation and six genes, including NDUFA5, ATP5O and ADRBK1, were associated with the force of heart contraction (Tables II-IV) . Pathway enrichment analysis of DEGs. The DEGs identified in the present study were enriched in nine pathways (Table V) . The RVTE DEGs were mainly enriched in ribosomal pathways (P=1.59x10 -23 ), Parkinson's disease (P=0.007) and oxidative phosphorylation (P=0.008). The SVTE DEGs were enriched in ribosomal pathways (P=4.58x10 -19 ) and cardiac muscle contraction (P=0.025). The non-overlapping DEGs were enriched in ribosomal pathways (P=2.25x10 -6 ) and protein export (P=0.03).
Metabolic pathway visualization analysis of specific DEGs of RVTE.
The metabolic pathways were visualized in schemes depicting the ribosomal pathway (Fig. 2) and the protein export pathway ( Fig. 3 ; http://www.genome.jp/kegg/tool/map_ pathway2.html). In the ribosomal pathway, RPL21, RPS21, RPS24 and RPS27 were upregulated and in the protein export pathway, SRP9 was upregulated. The results suggested that these genes may be critical in RVTE and that certain variations in the expression of these genes may lead to an increased risk of recurrence.
Discussion
In recent years, the application of adequate thromboprophylaxis has led to significant progress in the management of VTE by successfully reducing morbidity and mortality (21) . However, to date, methods for effectively preventing and diagnosing SVTE and RVTE have remained controversial (22) . The present study used bioinformatics methods to investigate the molecular mechanisms and potential biomarkers of SVTE and RVTE. In the present study, gene expression profiles of whole blood samples were successfully used to screen for DEGs in specimens from patients with SVTE compared with those in control specimens. With regard to enriched biological processes and pathways for DEGs in SVTE, genes involved in ribosomal pathways, including RPS3A and RPS7, and mitochondrial function, including UQCRQ and COX7C, were indicated to be most consistently affected and modulated. Ribosomal proteins have remained highly conserved during evolution and reflect critical functions in ribosome biogenesis; in addition, several ribosomal proteins were shown to have extra-ribosomal functions in apoptosis, DNA repair and genetic disease (23) . A total of 12 DEGs were involved in ribosomal pathways. A paucity of studies have explored the pathogenesis of VTE. It has previously been indicated that the ribosomal-related RP-MDM2-P53 axis may be involved in the molecular pathogenesis of the 5q syndrome, and VTE was reported in 3% of patients with 5q syndrome (24). COX7C and UQCRQ are constituents of the mitochondrial respiratory chain (25) . Mutations of these two genes may increase oxidative stress in coronary artery disease (26) . The mortality after VTE is strongly associated with presentation of underlying cardiovascular disease (27) . First-time VTE in numerous patients is idiopathic and challenging to diagnose, while COX7C and UQCRQ may represent novel biomarkers to identify SVTE. The specific DEGs in RVTE were found to be mainly involved in ribosomal pathways, heart contraction and oxidative phosphorylation. Pathway visualization revealed that RPL21, RPS21, RPS24 and RPS27, which all encode ribosomal proteins, were enriched in ribosomal pathways, while SRP9 was enriched in the protein export pathway. Furthermore, RPL21, RPS21, RPS24 and RPS27 were found to be involved in RVTE through critical ribosome biogenesis or extra-ribosomal functions; of note, the expression of these genes was upregulated in patients with RVTE but unchanged in patients with SVTE. It has been reported that certain diseases, including transient ischemia/reperfusion and pre-eclampsia, are associated with ribosomes (28, 29) . RPS24 mutation was potentially linked to pathologies of Diamond-Blackfan anemia (30) . The above results suggested that RPL21, RPS21, RPS24 and RPS27 may have critical roles in RVTE.
The results of the present study showed that β-adrenergic receptor kinase 1 (ADRBK1) was closely associated with RVTE and involved in heart contraction. Polymorphisms in ADRB2 and LPL genes are known to have central roles in vascular biology (31) . A previous study suggested that the use of ADRBK1 as a biomarker significantly improved heart failure therapy (32) . Certain studies showed that the ADRBK1/phosphoinositide-3 kinase (PI3K) complex improved cardiac function and that PI3K-dependent phosphorylation of ADRBK1 on Ser670 is responsible for the downregulation of ADRBK1 protein via a proteasome-dependent pathway (33, 34) . Furthermore, PI3K influences insulin-like growth factor and blood vessel-related factor through G protein beta gamma (35) . These results may suggest that ADRBK1 has a critical role in RVTE by serving as a dual effector of the compensatory myocardial diastole and the PI3K response.
The present study also identified NDUFA5 and ATP ATP5O as DEGs, which were significantly associated with oxidative phosphorylation. The oxidative stress injury and exitotoxicity in mitochondria induced by NDUFA5 and ATP5O have been proved to be the cause of a variety of nervous system degenerative diseases, including Parkinson's, Alzheimer's and Huntington's disease (36, 37) . Free-radical generation and consequent oxidative stress in platelet activation and thrombotic vascular diseases have a distinctive role with the potential injurious effects of homocysteine (38, 39) . Therefore, NDUFA5 and ATP5O inducing oxidative stress injury and exitotoxicity in mitochondria may also have an impact on RVTE.
In conclusion, the screening performed in the present study identified 42 DEGs in RVTE, including 35 up-and 7 downregulated genes, 20 DEGs in SVTE, including 17 up-and 3 downregulated genes, and 22 specific DEGs in RVTE. Furthermore, functional and pathway enrichment analysis was performed for these identified DEGs. The results indicated that DEGs in SVTE, including COX7C and UQCRQ, may be used as potential biomarkers for SVTE and that specific DEGs in RVTE, including ADRBK1, NDUFA5 and ATP5O, may be considered as potential biomarkers of RVTE. However, experimental studies are required to confirm these results. 
